BMY Earnings & Financial Statements
Bristol-Myers Squibb Company
$59.28
+$2.61(+4.61%)
63
Overall
90
Value
45
Tech
55
Quality
Market Cap
$121.09B
Volume
13.69M
52W Range
$42.52 - $68.64
Target Price
$66.19
BMY earnings and financial statements: Bristol-Myers Squibb Company's income statement, balance sheet and cash flow statement, annual and quarterly.
BMY Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| Cost of revenue | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B |
| Operating income | $17.04B | $14.76B | $17.24B | $18.70B | $29.74B |
| EBITDA | $15.23B | $3.15B | $19.35B | $19.22B | $20.12B |
| Net income | $7.05B | -$8.95B | $8.03B | $6.33B | $6.99B |
| EPS (diluted) | $3.46 | $-4.41 | $3.86 | $2.95 | $3.12 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $90.04B | $92.60B | $95.16B | $96.82B | $109.31B |
| Total liabilities | $71.53B | $76.22B | $65.67B | $65.70B | $73.31B |
| Shareholders’ equity | $18.47B | $16.34B | $29.43B | $31.06B | $35.95B |
| Cash and equivalents | $10.21B | $10.35B | $11.46B | $9.12B | $13.98B |
| Long-term debt | $42.85B | $47.60B | $36.65B | $35.06B | $39.60B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $14.16B | $15.19B | $13.86B | $13.07B | $16.21B |
| Capital expenditure | -$1.31B | -$1.25B | -$1.21B | -$1.12B | -$973.00M |
| Free cash flow | $12.85B | $13.94B | $12.65B | $11.95B | $15.23B |
| Dividends paid | $5.04B | $4.86B | $4.74B | - | $4.40B |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BMY | $59.28 | +4.6% | 13.69M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Bristol-Myers Squibb Company Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW